Invicro has a vast range of tools that help accelerate your drug discovery and development process. Our technology platforms support key decision-making in:
- Early discovery and screening
- Candidate selection
- First-in-human translation and early development
- Late stage, multi-center determination of efficacy
We have experience working with a wide range of therapeutics, including small molecules, peptides, proteins, antibodies, multi-specific proteins, CAR-T cells, viruses, antisense oligonucleotides (ASO), DNA, RNA and others. Invicro strives to answer a wide array of biological questions, including but not limited to:
- Target density (Bmax)
- Binding affinity (KD)
- Target engagement
- Target occupancy, impact of dosing regimens, and route of administration
- Biodistribution and pharmacokinetics (ADME, DMPK)
Invicro offers in vitro assays, in vivo imaging and ex vivo tissue imaging across resolutions and sensitivities. We design studies that combine different technologies spanning various platforms, including:
- IVIS Bioluminescence
- IVIS Fluorescence
- Fluorescence Molecular Tomography (FMT)
- Optoacoustic Tomography (MSOT)
- AAALAC accredited facilities
- All Major Disease Areas
- All Major Tumor Models
- All Major Research Species
- Clinical Imaging
- Veterinary Radiology
Imaging and Radioisotopes
- Cryo-fluorescence tomography (CFT)
- ex vivo fluorescence reflectance imaging
- Confocal microscopy
- Autoradiography & micro-autoradiography
- Homogenate radioligand binding assays
- Gamma counting and liquid scintillation
- Frozen and fixed tissue histology
- Quantitative immunohistochemistry (Q-IHC) using high sensitivity tissue testing (HSTT) platform
- Flow cytometry
- Clinical chemistry
- CBC Analysis
in vitro and Chemistry
In Vitro Assays
- Cell Culture
- Cell binding and competition
- Tissue homogenate binding
Imaging Agent Chemistry
- Imaging agent radiolabeling
- Oligos to Antibodies
- Fluorescent labeling
Invicro leverages advanced tools to provide solutions to various questions in preclinical animal models (rodent to NHP) and in translational work in humans, including:
- What is the in vivo distribution of a compound following intrathecal administration?
- Does a compound cross the BBB?
- What is the rate of clearance and route of elimination of a novel antisense oligonucleotide (ASO)?
- What is the fate of the cargo with respect to the carrier (e.g., for an antibody drug conjugate or a drug loaded liposome)?
- What is the integrity of a novel implant material over time?
- Does a novel alpha radiopharmaceutical exhibit tumor cell internalization in vivo?
- What is the fate and persistence of my therapeutic T cells?
- Where and for how long is my gene of interest delivered and expressed?
PD biomarkers and efficacy
- Does my anti-cancer therapeutic inhibit tumor growth in an orthotopic, transgenic, or metastatic tumor model?
- Can tumor accumulation of a novel radiolabeled compound predict treatment response?
- Are there synergistic effects when combining an alpha radiopharmaceutical with an immunotherapy agent?
- Does colon wall thickness in an animal model of IBD change following treatment?
- Does my anticancer therapeutic decrease tumor burden in my deep tissue tumor model?
- Does liver fat fraction or fibrosis stabilize or decrease with my treatment?
- Does my immune-modulator increase T cell activation in a tumor, and with what timing?
- What is the receptor occupancy of a compound following oral dosing?
- Does my targeted biologic bind preferentially in a target expressing tumor vs. a target negative tumor?
- Does my novel drug delivery system (e.g. virus) reach its target in vivo?
- What is the estimated human dosimetry (absorbed dose) for a novel radiotracer?
- Is there angiogenesis surrounding a surgical implant?